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The accumulating evidence of the beneficial effects of cinnamon (Cinnamomum burmanni) in type-2 diabetes,
a chronic age-associated disease, has prompted the commercialisation of various supplemental forms of the
spice. One such supplement, Cinnulin PF†, represents the water soluble fraction containing relatively high
levels of the double-linked procyanidin type-A polymers of flavanoids. The overall aim of this study was to
utilize genome-wide mRNA-Seq analysis to characterise the changes in gene expression caused by Cinnulin
PF in immortalised human keratinocytes and microvascular endothelial cells, which are relevant with respect
to diabetic complications. In summary, our findings provide insights into the mechanisms of action of
Cinnulin PF in diabetes and diabetic complications. More generally, we identify relevant candidate genes
which could provide the basis for further investigation.
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D
iabetes is a highly debilitating metabolic disorder
which can lead to life-threatening complications
as a result of uncontrolled hyperglycemia, and is
becoming an increasingly significant disease in elderly
populations. Historically, many plant products have been
used as treatments for diabetes, with varied success. One
such plant product is cinnamon, a spice produced from
the bark of trees from the genus Cinnamomum. Studies
have shown that cinnamon has potent antioxidant and
anti-inflammatory activities. In vitro, a 20-fold enhance-
ment in insulin-dependent glucose metabolism following
treatment with cinnamon has been shown (1). The active
water soluble components of cinnamon have been
identified as double-linked procyanidin type-A polymers,
mainly trimers and tetramers (Fig. 1) (1). These procya-
nidins are naturally occurring polymers of flavonoids
such as catechin which are well known to be potent
antioxidants.
Water soluble components of cinnamon have been
shown to result in the autophosphorylation of the insulin
receptor, as well in specific inhibition of the phosphotyr-
osine phosphatase, which dephosphorylates the insulin
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receptor (2). Findings from an in vivo study demonstrated
that when an aqueous cinnamon extract was admini-
strated orally (300 mg/kg), there was an 18% increase in
phosphorylation levels of the insulin receptor-b and 33%
insulin receptor substrate-1 compared to control rats (3).
Overall, the findings suggested that the water soluble
component of cinammon can increase insulin sensitivity,
by increasing glucose uptake in skeletal muscle (3). In a
clinical study, it was shown that 500 mg per day of
Cinnulin PF† (CPF, a commercial cinnamon extract
containing the bioactive double-linked procyanidin type-
A trimers and tetramers) resulted in improvements in
fasting blood sugar levels, systolic blood pressure and
body composition in participants with metabolic syn-
drome (4).
Although there is accumulating evidence of the bene-
ficial effects of cinnamon in diabetes, few studies have
investigated the molecular mechanisms accounting for
these observations. In particular, mechanisms related to
the effects of cinnamon in diabetic complications are very
limited. Major complications of diabetes include diabetic
foot ulcers, which arise as a result of impaired wound
healing in lower extremities and endothelial dysfunction
which can lead to cardiovascular conditions such as
atherosclerosis (Fig. 2) (57). The overall aim of this
study was to investigate the effects of the water
soluble component of cinnamon, using CPF, on gene
expression changes by genome-wide mRNA-Seq analysis
in representative, human keratinocyte and microvascular
endothelial cell lines.
Materials and methods
Cinnulin PF preparation
The water soluble component of cinnamon bark (Cinna-
monum burmanii), Cinnulin PF† (CPF), containing 4.5%
(page number not for citation purpose)
Fig. 1. Double-linked type-A procyanidin polymer (trimer) (A). Comprised of the flavanoid catechin (B), which is made up of two
substituted benzene rings, and a substituted dihydropyran ring.
Fig. 2. The different factors which lead to impaired wound healing in diabetes.
Haloom Rafehi et al.
2
(page number not for citation purpose)
Citation: Pathobiology of Aging & Age-related Diseases 2012, 2: 11905 - DOI: 10.3402/pba.v2i0.11905
type-A polymers (trimeric and tetrameric) was a generous
gift from Integrity Nutraceuticals International (USA).
The powder was accurately weighed and dissolved in
phosphate buffered saline without calcium and magnesium
(PBS) by gentle rotation at room temperature for 3060
minutes (70% soluble). The mixture was then centri-
fuged for five minutes at 400g. The supernatant was
collected, sterilized by filtration (0.22 mm) and concen-
trated stocks (10 mg/mL) were stored at 808C until use.
Cell culture
Human microvasuclar endothelial, HMEC-1, cells were
cultured in MCDB-131 medium (Invitrogen, Carlsbad,
CA, USA), supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 10 ng/mL epidermal growth factor
(EGF), 5000 units/L heparin, 200 mM hydrocortisone,
GlutaMAXTM-1 (Invitrogen) and 20 mg/mL gentamicin.
Human keratinocytes (FEP-1811) were grown in kerati-
nocyte-SFM (K-SFM) medium (Invitrogen, serum-free
medium) supplemented with L-glutamine, epidermal
growth factor, bovine pituitary extract and 20 mg/mL
gentamicin (8). Cells were grown in a humidified 5% CO2
environment at 378C. As required, single cell suspensions
were prepared by trypsinization (0.05% trypsin/EDTA
solution, Invitrogen) for 510 minutes. Cell numbers were
determined using a hemocytometer.
Cell viability and apoptosis
CellTiter-Blue† and ApoOne homogeneous Caspase
3/7† kits where used to examine the effects of CPF on
cell viability and apoptosis, respectively, according to the
manufacturer’s instructions (Promega, Madison, WI,
US). Cells were treated with CPF at a concentration
range of 02048 mg/mL. Following a 24 hour incubation
at 378C, 5% CO2, CellTiter-Blue reagent was added and
incubated at 378C, 5% CO2 for four hours or ApoOne
buffer/substrate solution was added and incubated in the
dark for two hours at room temperature. Fluorescence
was measured using a VICTOR 3 (PerkinElmer,
Waltham MA, USA) microplate reader. The EC50 was
defined as the concentration of CPF which results in 50%
reduction in cell viability.
Cell cycle analysis
HMEC-1 and keratinocyte cells were treated with various
concentrations of CPF (0200 mg/mL) for 24 hours, after
which cells were harvested with 0.05% trypsin, washed
with PBS, resuspended in ice-cold PBS containing 2%
FBS and fixed overnight with 70% ethanol by continuous
rotation at 58C. Cells were stained with an overnight
incubation at 58C in 100 mg/mL propidium iodide
containing 1 mg/mL RNase A (Qiagen Inc., Valencia,
CA). Samples were analyzed by flow cytometry (Facs
Calibur, Becton Dickinson, Franklin Lakes, NJ, USA).
Fluorescent debris were gated using forward scatter
versus orthogonal side scatter and a secondary gate was
placed around the single cell population using a pulse
area versus pulse width dot plot. The percentage of cells
in each phase of the cell cycle was analyzed using FlowJo
V7.6 flow cytometry analysis software (Tree Star Inc.,
Ashland, OR, USA).
Migration scratch assay
HMEC-1 and keratinocytes were plated in 6-well plates.
At 80% confluency and typically following a 24 hour
period of supplement starvation, cells were treated with
various concentrations of CPF (050 mg/mL) for one
hour. Cells were washed with PBS and a single scratch
was performed across the centre of the well using a 1 mL
pipette tip. Cells were then washed twice with PBS and
fresh medium was added. Digital images were acquired at
defined points at the time of the scratch and after
24 hours at the same location, at a magnification of x4
using a camera (Olympus DP20) and light microscope
(Olympus CKX4).
Total RNA isolation and cDNA synthesis
Cells were treated with CPF (20 and 100 mg/mL for
keratinocytes, 20 mg/mL for HMEC-1 cells) for 24 hours.
Total RNA was isolated using TRIZOL (Invitrogen).
Cells suspended in TRIZOL were passed through a
21-gauge needle five times to ensure proper lysis, then
RNA extraction was performed following the Qiagen
protocol. Genomic DNA contamination was removed by
DNAse treatment (Qiagen). First strand cDNA synthesis
was performed using High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Carlsbad, CA,
USA), according to the manufacturer’s instructions.
Library construction and RNA sequencing
RNAseq libraries were prepared according to Illumina
mRNAseq library preparation kit (Illumina Inc. San
Diego, CA, USA, cat # RS-100-0801). Briefly, 8 mg of
total RNA was taken for mRNA isolation using poly-T
oligo-attached magnetic beads. Poly-A mRNA was frag-
mented with the presence of divalent cations under
elevated temperatures. The mRNA fragments were re-
verse transcribed via SuperScript II (Invitrogen) with
random primers. The second strand was synthesized with
addition of RNaseH and DNA Pol I. Double stranded
complementary DNA (cDNAs) were end-repaired, fol-
lowed by 3? adenylation using Klenow fragment (3? to 5?
exo minus). Then Illumina paired end adapters with
T- overhangs at their 3? end were ligated to the cDNAs.
Following column purification (Qiagen MinElute), to
remove excess of unligated adapter, library cDNA was
separated on a 2.0% agarose gel. Library cDNA in the
range of 200 bp910 bp fragments were isolated by gel
purification (Qiagen) and amplified with 15 cycles of
Phusion DNA polymerase mediated PCR (10s 988C, 30s
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658C, 30s 728C) using oligonucleotides complementary to
Illumina sequencing adapters. Column purified libraries
were quantified fluorometrically (Invitrogen), and visua-
lised by MultiNA (DNA 2500 kit) electrophoresis for
quality assurance. Libraries were diluted to 10 nM and
stored at 208C prior to cluster generation. Denatured
DNA samples were diluted to 6 pM prior to cluster
generation (v4 cat # GD-103-4001). Flow cell sequencing
of 36 bp tags was conducted on a Genome Analyzer II
apparatus (Illumina) according to the manufacturer’s
protocols using v4 sequencing reagents (cat # FC-104-
4001).
Quantitive reverse transcriptase PCR (qPCR)
PCR amplification was performed using an Applied
Biosystems 7500 Fast Real-Time PCR System. Primers
used in the validation were HPRT-1 (F: TGACACTGG
CAAAACAATGCA, R: GGTCCTTTTCACCAGCAA
GCT), HMOX-1 (F: TCCCCTCGAGCGTCCTCAGC, R:
TGGGGCATGCTGTCGGGTTG), VEGFA (F: TGAG
GAGTCCAACATCACCA, R: TCTCTCCTATGTGC
TGGCCT), VEGFB (F: CCACCAGAGGAAAGTGG
TGT, R: ATGAGCTCCACAGTCAAGGG), CASP-1
(F: CCACAATGGGCTCTGTTTTT, R: CATCTGG
CTGCTCAAATGAA), JUNB (F: CACCTCCCGTT
TACACCAAC, R: GGAGGTAGCTGATGGTGGTC),
JUND (F: CGCCTGGAAGAGAAAGTGAA, R: GTT
GACGTGGCTGAGGACTT), MMP1 (F: CAGAGGG
AGCTTCCTAGCTG, R: AGTGGAGGAAAGCTGTG
CAT), SOD-2 (F: CAGTGTGCGGCACCAGCAGG, R:
TGAGGTTCCAGGGCGCCGT), ICAM-1 (F: GGC
CACGCATCTGATCTGTA, R: CACTTCCCCTCTCA
TCAGGC), p50 (F: ACTGCCAACAGCAGATGG
CCCA, R: GCACCAGGTAGTCCACCATGGG).
5 pmoles of forward and reverse primer, cDNA template
and FAST SYBR† Green Master Mix (Roche, Indiana-
polis, IN, USA) were mixed to a final volume of 20 ml.
Reactions were incubated at 958C for 10 min, followed by
40 cycles of 958C for 10 s and 608C for 30 s. Analyzed
genes were normalized to the level of HPRT1.
Analysis
Sequencing was performed at a depth of 20 million
mapped reads per sample. The number of sequence reads
and alignment statistics are shown in Table 1. Reads
generated by the Illumina base calling software V1.6 were
aligned with Burrows Wheeler Aligner to the human
transcriptome database curated by RefSeq (Hg18 build).
Raw counts were normalised to adjust for slightly
differing data volume across lanes giving the widely
used score reads per transcript per million reads. These
scores were used to determine relative fold changes and
the conventionally used91.5 fold-change, which is dis-
cernable with qRT-PCR was defined a significant change
in expression. The online program MetaCore (GeneGo
Inc. St. Joseph, MI, USA) was used for pathway analysis.
GeneGo is a commercial pathway analysis package
however those interested can further investigate pathways
discussed in this manuscript using freely available
packages such as DAVID functional annotation tools
(http://david.abcc.ncifcrf.gov/tools.jsp).
Data is expressed as the mean9SD, and where
relevant, statistical analysis was performed using a one-
way Anova followed by a Dunnett’s test where *pB0.05
was considered statistically significant.
Results
CPF induces a dose-dependent decrease in cell
viability and increased apoptosis in HMEC-1 and
keratinocytes
The effect of CPF on cell viability and induction of
apoptosis in HMEC-1 and keratinocyte cells was assessed
using the CellTiter-Blue and ApoOne Homogeneous
Caspase 3/7 assay kits (Fig. 3). The findings indicate
that CPF induces a dose-dependent decrease in cell
viability in both cell lines. The EC50 values were
calculated to be 416 and 663 mg/mL for HMEC-1 and
keratinocyte cells, respectively (Fig. 3A,B). Similarly, the
caspase activity data indicated a concentration-depen-
dent increase in apoptosis in both HMEC-1 and kerati-
nocytes (Fig. 3C,D). The effect of CPF on the cell cycle
was accessed using PI staining and FACS analysis. Cell
cycle analysis indicated that CPF had minimal effects on
the different stages of the cell cycle, except for the
increase seen in the percentage of cells in the sub-G1
population in both cell lines at 100 and 200 mg/mL
(Fig. 4).
Table 1. Sequence reads and alignment statistics for mRNA-seq experiments
HMEC-1 Keratinocytes
Untreated CPF 20 mg/mL Untreated CPF 20 mg/mL CPF 100 mg/mL
Total reads 27500928 24518899 24780637 27716895 27984648
Mapped reads 22554037 20981983 20517834 23152109 22764111
% aligned 82.0 85.6 82.8 83.5 81.3
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CPF enhances migration at 20 mg/mL in both
HMEC-1 and keratinocytes
To determine the effect of CPF on cell migration in vitro,
a scratch migration assay was used in HMEC-1 and
keratinocytes. It was found that in both cell lines, CPF
promoted cell migration at the lower concentrations
investigated compared to the untreated controls following
a one hour treatment and 24 hour incubation, with the
effect being most profound at 20 mg/mL in both the
HMEC-1 cells and keratinocytes (Fig. 5). However, CPF
was not effective at promoting cell migration at higher
concentrations.
CPF alters the expression levels of a finite number of
genes
To determine the effect of CPF on genome-wide gene
expression, mRNA sequencing was performed by next
generation sequencing (NGS), using keratinocytes treated
at 20 and 100 mg/mL and HMEC-1 cells treated at 20 mg/
mL for 24 hours; gene expression levels were compared to
the relevant untreated controls. The 20 most up and down
regulated genes for each treatment group is indicated in
Table 2 and more detailed characteristics of each of the
genes are described in supplementary Tables 13. The
mRNA-Seq findings indicate that the greatest changes in
genes expression levels was found in keratinocytes treated
with 100 mg/mL CPF, with 8% percent of genes up
regulated and 11% down regulated (Fig. 6A). By
comparison, 4% of genes were up regulated and 3%
down regulated in keratinocytes treated with 20 mg/mL,
and 6% up regulated and 5% down regulated in HMEC-1
cells treated with 20 mg/mL CPF (Fig. 6A). A comparison
of the mRNA-Seq data for the two cell lines indicated
that there was very little overlap between the genes up
and down regulated in keratinocyte and HMEC-1 cells
treated with 20 mg/mL CPF (Fig. 6Bi). As expected a
large overlap was observed between the up and down
regulated genes for the low and high CPF concentrations
in keratinocytes however, there are certain genes which
are up or down regulated at 20 mg/mL which are either
unchanged at 100 mg/mL or regulated in the opposite
direction (Fig. 6Bii). RT-PCR was used to validate
mRNA-Seq findings and positive correlation was identi-
fied for validated genes (Fig. 7).
Fig. 3. Cell viability and apoptosis. Graphs showing the relative survival and EC50 (mg/mL) values following 24 hour incubations with
CPF (0, 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 1024 mg/mL), in HMEC-1 (A) and keratinocytes (B) using the CellTiter-Blue† Assay. The
results of the ApoOne homogeneous 3/7† assay indicating caspase activity in HMEC-1 (C) and keratinocytes (D) cells treated with
various concentrations of CPF for 24hrs. The data is representative of at least two independent experiments and is presented as the
mean9SD of triplicate determination from a single experiment. *indicates pB0.05, compared to the control.
Cinnulin PF in diabetes
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CPF alters the expression of genes related to the cell
cycle, DNA replication and repair and apoptosis at a
high concentration
Down regulation of genes involved in cell cycle regula-
tion, DNA replication and repair was seen in keratino-
cytes treated with 100 mg/mL of CPF (Table 3). For
example, there was extensive down regulation of cyclins
and cyclin dependent kinases, which are proteins essential
for the regulation of the different stages of the cell cycle.
Further, down regulation of important DNA replication
genes such as DNA polymerase and topoisomerase were
also observed. Down regulation of genes such as BRCA-1
and p53 results in impaired DNA repair. There was also a
corresponding increase in genes involved in apoptosis.
For example, BAX is involved in initiating the mitochon-
drial apoptotic pathway, while BIM, BIK and PUMA
block proteins required for normal mitochondrial func-
tion (Table 3).
CPF alters the expression of genes involved in
proliferation, migration and wound healing at
20 mg/mL in both HMEC-1 and keratinocytes
Up regulation of genes involved in proliferation and
cellular migration was observed in both HMEC-1 cells
and keratinocyte cells treated with 20 mg/mL CPF
(Table 4). For example, in keratinocytes there is up
Fig. 4. Graph showing the average % of cells in the different phases of the cell cycle in HMEC-1 cells (A) and keratinocyte cells (B).
Cells were incubated with CPF for 24 hours, fixed and stained with propidium iodide. The proportion of cells in the different stages of
the cell cycle was determined by FACS analysis. The data is representative of two independent experiments and is expressed as the
mean9SD from a single experiment performed in duplicate. CE show graphs of the cell cycle distribution of keratinocyte cells and
FH HMEC-1 cells treated with CPF at 0 (C, F), 20 (D, G) and 100 (E, H) mg/mL.
Haloom Rafehi et al.
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Fig. 5. CPF promotes cell migration at low concentrations. Images are of keratinocytes (top) and HMEC-1 cells (bottom) treated with
various concentrations of CPF (0, 10, 20 and 40 mg/mL) for 1 hour. Scratches were performed immediately following the incubation and
images were taken at 0 hrs (representative images shown) and 24 hrs post scratching; magnification4. Data is representative of five
independent experiments for keratinocytes and two independent experiments for HMEC-1.
Fig. 6. (A) The% of transcripts up/down regulated for the three treatment groups. HMEC-1 cells were incubated with 20 mg/mL CPF
and keratinocytes were incubated with 20 and 100 mg/mL for 24 hours. Significant gene changes were based on a fold change of91.5
compared to the relevant untreated control. (B) Venn diagrams showing the number of genes up and down regulated in HMEC-1
and keratinocyte cells treated with CPF (20 mg/mL) for 24 hours (i) and in keratinocytes treated with 20 and 100 mg/mL CPF for
24 hours (ii).
Cinnulin PF in diabetes
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Table 2. The top 20 most up/down regulated genes by CPF in the three treatment groups
Keratinocytes 20 mg/mL Keratinocytes 100 mg/mL HMEC-1 20 mg/mL
UP Gene Fold change UP Gene Fold change UP Gene Fold change
1 TM4SF19 18.15 1 TM4SF19 41.71 1 CRYAB 15.93
2 G0S2 7.06 2 NDRG1* 26.86 2 CRLF1 11.42
3 NDRG1* 6.6 3 KRT17 21.93 3 PTGDS 6.11
4 NDRG1* 5.72 4 GDF15 15.6 4 SOX18 5.93
5 IL6 4.97 5 HMOX1 15.22 5 BCYRN1 5.51
6 ITGA2 4.81 6 S100P 13.79 6 MIR762 (includes
EG:100313837)
5.37
7 RELB 4.74 7 SAT1* 12.31 7 FOS 5.25
8 MALL 4.59 8 ITGA2 12.27 8 ID1* 4.88
9 GPR109A 4.51 9 G0S2 11.54 9 PGF 4.77
10 TLR2 4.26 10 TRIB1 10.69 10 TRNP1 4.36
11 LAMB3* 3.88 11 TLR2 10.46 11 SYT15* 4.19
12 BHLHE40 3.87 12 AREG 10.4 12 FBLN5 3.89
13 SAA1* 3.72 13 ATF3* 9.8 13 C4ORF48* 3.8
14 LAMC2* 3.7 14 LCN2 9.73 14 SNORD36B 3.76
15 COL6A2* 3.69 15 FABP3 8.72 15 SNORD114-3 3.76
16 LAMB3* 3.69 16 LAMB3* 8.41 16 JUNB 3.72
17 AREG 3.65 17 ATF3* 8.11 17 LYL1 3.52
18 LAMB3* 3.64 18 HSD17B14 7.99 18 HCN2 3.52
19 KRT17 3.59 19 SOD2* 7.82 19 HES4* 3.5
20 LAMC2* 3.57 20 DHDH 7.77 20 METRN 3.44
DOWN DOWN DOWN
1 TNNI2* 8.91 1 ALPP 14.99 1 SNORD84 5.58
2 TNNI2* 8.46 2 HPDL 13.57 2 RN18S1 4.92
3 SYT8 8.24 3 C10ORF114 12.24 3 RN7SK 4.91
4 H19 6.05 4 MIR675 (includes
EG:100033819)
10.4 4 RMRP (includes
EG:6023)
4.78
5 SNORD96A (includes
EG:619571)
6.02 5 H19 10.14 5 SNORD81 4.65
6 TNNI2* 5.8 6 PROM2* 8.04 6 MIR1978 4.52
7 ANKRD2* 5.78 7 IGFBP3* 7.94 7 SNORA11 4.03
8 5.28 8 SNORD31 6.66 8 APLN 3.96
9 MIR663B 5.21 9 TMEM139 6.64 9 SCARNA9L 3.84
10 MIR675 (includes
EG:100033819)
4.98 10 PDLIM2* 6.12 10 SNORD14D (includes
EG:85390)
3.72
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regulation of the genes expressing the EGF-R ligands
amphiregulin and HB-EGF. In HMEC-1 cells, there was
up regulation of the transcription factors c-FOS and c-
JUN, as well as PDGF-B. Also, in keratinocytes up
regulation of genes involved in migration, including
integrins, amphiregulins and HB-EGF was observed. In
HMEC-1 cells, genes changes associated with migration
included the up regulation of PDGF-B and integrins
(Table 4).
Further, changes in the expression of inflammation-
associate genes were observed in both HMEC-1 and
keratinocytes treated with 20 mg/mL CPF (Table 4). TGF-
b1 was up regulated in HMEC-1 cells while the receptor
was also up regulated in keratinocyte cells at 20 mg/mL.
While production of IL-6 was increased in keratinocyte
cells, it was decreased in HMEC-1 cells. CCL2 (macro-
phage chemotactic protein) was also down regulated in
HMEC-1 cells. In addition, a number of gene expression
changes were observed in both cell lines at 20 mg/mL CPF
which may be beneficial for the promotion of wound
healing (Table 4). For example, in HMEC-1 cells there
was up regulation of TIMPs, with a corresponding,
general decrease in MMP expression levels, which is
important for extracellular matrix formation and re-
epithelialisation. There was also up regulation of genes
involved in angiogenesis, including PDGF-B in HMEC-1
cells, and HIF-1a and VEGF in keratinocytes (Table 4).
CPF induces changes in the expression of genes
related to endothelial cell function
Up regulation of superoxide dismutase was observed in
keratinocyte cells (Table 4). In HMEC-1 cells the expres-
sion of numerous genes which may be either detrimental
or beneficial to endothelial cell function was following
treatment with 20 mg/mL CPF. Beneficial changes include
the upregulation of eNOS, while potentially detrimental
changes include the up regulation of genes encoding for
endothelin-1, protein kinase C and PAI-1 (Table 4).
Discussion
We investigated the effects of a water soluble cinnamon
extract, CPF, in the context of diabetic complications, by
examining gene expression changes in human keratino-
cytes and HMEC-1 cells by mRNA-Seq. When examin-
ing the mRNA-Seq data it is important to consider that
the main aim of this study was to identify potential gene
targets for further investigation. Much of the following
discussion is speculative on the basis of the gene
expression analysis in the context of diabetic complica-
tions. Only changes in gene expression and not the
functional endpoint of gene expression  i.e. synthesis
of a functional protein, post-translational modifications 
were examined in this study. Further issues when using
crude extracts are related to modifications which occur in
vivo (e.g. conjugation reactions) and bioavailability of theT
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active components in cells. The uptake of polyphenolic
compounds have been examined in numerous studies, and
a number of studies have investigated the effects various
cinnamon extracts in cell culture systems indicating the
intracellular absorption of relevant compounds (914). In
this context, in vivo bioavailability is also an important
consideration. Although studies have reported that
procyanidins are bioavailable in rodents and humans,
the issue remains largely controversial and requires
further exploration.
Our initial experiments indicate that CPF promotes
migration at concentrations between 10 and 20 mg/mL
in both keratinocytes and HMEC-1 cells (Fig. 4).
Although we performed detailed time-course studies,
using cell viability, apoptosis and migration, we speci-
fically chose to closely investigate treatment with 20 mg/
mL at 24 hours to reflect a non-toxic/non-apoptotic
concentration of the formulation in both cell lines.
mRNA-Seq analysis indicated that numerous genes
associated with diabetic wound healing were regulated
by CPF (Table 4). For example, certain integrins which
are transmembrane glycoproteins involved in cell migra-
tion by interacting with components of the extracellular
matrix such as laminin 1, fibronectin and collagen (types
I, II and IV), were up regulated by CPF in both cell
lines. Further, platelet derived growth factor B (PDGF-
B) was up regulated 2.18 fold in HMEC-1 cells and
fibroblast growth factor-2 (FGF-2) was found to be
increased 1.75 fold in keratincoytes treated with 20 mg/
mL CPF (Table 4). FGF-2 has been shown to induce
keratinocyte migration in vitro and has also been
strongly associated with promoting angiogenesis (15).
Other proteins involved in migration pathways that were
found to be up regulated by CPF include CDC42, Fyn
and PAK1. Furthermore, up regulation of the epidermal
growth factor receptor (EGF-R) ligands amphiregulin
and heparin binding epidermal growth factor (HB-EGF)
in keratinocyte cells.
An aspect which leads to impaired diabetic wound
healing is the prolonged inflammatory phase which
prevents the progression of the healing process. This is
associated with decreased expression of cytokines, in-
cluding IL-10, IL-6, TGF-b1 and receptors TGF-bR-I
and TGF-bR-II (1619). It was found that CPF increased
the expression of TGF-b1 in HMEC-1 cells but not in
keratinocytes. Furthermore, TGF-bR-I mRNA expres-
sion was increased in keratinocyte cells treated with
20 mg/mL CPF, while expression of both receptors was
decreased in HMEC-1 cells (Table 4).
Fig. 7. RT-PCR (white, left) was used to validate the mRNA-Seq results (grey, right). Keratincoye (A) and HMEC-1 (B) cells were
treated with 20 mg/mL CPF for 24 hours. RNA was then isolated from the cells, and the RNA of a selected number of genes was then
amplified by RT-PCR. The results are expressed as the fold change in mRNA expression compared to untreated cells. RT-PCR results
represent the mean9SD from a single experiment performed in triplicate.
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Further, extracellular matrix (ECM) formation is
impaired in diabetic wound healing and increased
expression of matrix metalloprotienases (MMPs) has
been implicated (20). Although the expression of most
MMPs was not changed, expression of MMP-1 and
MMP-14 were both down regulated in HMEC-1 cells
(Table 4). This was associated with a corresponding
increase in the expression of some tissue inhibitors of
MMPs (TIMPs) in HMEC-1 cells. Angiogenesis, a
process which is essential for wound healing and the
delivery of nutrients and oxygen to the newly forming and
highly active granulation tissue, is also impaired in
diabetes. One reason for this is the decreased expression
of hypoxia inducible factor-1-alpha (HIF-1a) in response
to glucose. HIF-1a leads to the production of
growth factors needed for angiogenesis such as vascular
Table 3. Regulation of genes involved in DNA replication and repair, the cell cycle and apoptosis, following treatment of keratinocytes
and HMEC-1 cells with CPF
HMEC-1 Keratinocytes
Process Gene 20 mg/mL 20 mg/mL 100 mg/mL
DNA replication DNAPol o 2.29
DNAPol a 3.07
PCNA 1.51
TOP2 1.56 1.81
FEN1 2.09
DNA ligase 1 1.92
Cell cycle Cyclin A 2.59
Cyclin B 2.87
Cyclin D 1.61 2.05
Cyclin E
APC 1.68 1.76 1.77
CDK1 [p34] 1.51 2.35
CDK2 1.86
CDK4
CDK6 1.67
E2F1 2.63
E2F2 2.13
DP1 1.87
CDC25A 2.03
CDC25B
CDC25C 1.6
Aurora A 2.2
Aurora B 2.95
p21 2.07 5.34
GADD45a 1.74 2.92
GADD45b 1.76 1.96 3.07
DNA repair p53 1.83
BRCA1 1.77
ATM
ATR 1.57
PARP-1 2.3
Apoptosis FasR (CD95) 1.76
Caspase 3 1.52
Caspase 7 1.3
BAX 1.75
BIM 1.6
PUMA 3.56
BIK 5.57
BCL-XL 1.7
NOXA 1.78 2.66
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Table 4. The fold change of the expression of mRNA in genes involved in various processes, following treatment of keratinocytes and
HMEC-1 cells with CPF
HMEC-1 Keratinocytes
Process Gene 20 mg/mL 20 mg/mL 100 mg/mL
Proliferation c-FOS 5.25 4.09 3.82
c-JUN 1.61 1.93
AKT(PKB) 1.63 2.18
ERK1/2 1.66 1.73
Cell migration PDGF-B 2.18 2.23
Fyn 1.67 2.09
CDC42 1.56 1.66
PAK4 1.8
a2b1 integrin 4.81 12.27
a4b1 integrin 1.64 1.64
a5b1 integrin 2.1 2.55 4.28
a4b7 integrin 1.64
ITGA-5 2.1 2.55 4.28
FGF-2 1.75
FGF-5 2.02
Amphiregulin 3.65 10.4
HB-EGF 1.62 5.93
Anti-inflammatory TGF-b1 1.98
TGF-b2 1.58
TGF-bR-I 1.55 1.52 1.9
TGF-bR-II 1.7
IL-6 2.24 4.97 5.03
Wound healing (general) TIMP-1 1.78
TIMP-2 1.61 1.96
TIMP-3 1.7
MMP-1 1.82
MMP-14 1.59
MMP-15 1.76
LAMA3 3.88 8.41
CCL2 1.89
HIF-1a 1.62 2.18 1.97
PDGF-B 2.18 2.23
IL-8 1.69
VEGF-A 1.74 3.79
VEGF-B 1.5
VEGF-C 2.27 2.13
Antioxidant enzymes SOD2 3.12 7.82
PRDX2 1.74
Endothelial dysfunction eNOS 3.1
ET-1 1.75
PAI-1 1.86
ICAM-1 3.47 3.86
IL-6 2.24 4.97 5.03
Leptin R 2.8 2.14
RAGE 1.52 1.5
PKC 1.68 1.69 1.77
Erk (MAPK1/3) 1.66 1.73
MAP2K2 1.7
PI3K 1.8 2.33
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endothelial growth factor (VEGF) (21, 22). CPF
may improve angiogenesis by increasing HIF-1a
expression in keratinocytes and by the up regulation of
VEGF-A, VEGF-B and VEGF-C observed in the cell
lines (Table 4).
Endothelial dysfunction involves the altered pheno-
type of endothelial cells as a result of a number of
factors including decreased bioavailability of nitric oxide
(NO), increased oxidative stress, a pro-inflammatory
environment and increase in prothrombotic factors (23).
In the endothelium, NO is produced by endothelial NO
synthase (eNOS). It plays an important role in normal
vascular homeostasis and vasodilation and is helps to
protect the blood vessels from endogenous injury by
mediating a number of events. For example, eNOS
prevents leukocyte and platelet interaction with the
endothelial cells and inhibits VSMCs from proliferating
and migrating (2426). In endothelial dysfunction, NO
is degraded by ROS, and activation of the RAGE
receptor by increased AGE levels, resulting in decreased
eNOS activation. Although CPF lead to an increase in
the expression of the antioxidant enzyme superoxide
dismutase (SOD) in keratinocytes and decreased expres-
sion of RAGE, the same effects were not observed in
HMEC-1 (Table 4). However, eNOS expression in
HMEC-1 cells was increased, which could potentially
lead to increased expression of NO.
It should be noted that CPF also increased the
expression of a number of genes which could promote
endothelial dysfunction for example, endothelin-1 (ET-1),
a potent vasoconstrictor up-regulated in diabetes.
Further, insulin resistance results in the up regulation of
plasminogen activator inhibitor type-1 (PAI-1) and
adhesion molecules such as VCAM-1, ICAM-1 and E-
selectin via the MAPK pathway, which may contribute to
endothelial dysfunction (27, 28). CPF did not alter the
expression of the adhesion molecules however there was
an increase in the expression of PAI-1. Furthermore, up
regulation of a number of proteins involved in the MAPK
pathway in HMEC-1 cells  MAPK1/3 and MAP2K2 
which is already up regulated in the diabetes, was
observed.
Overall, our findings may provide some insights into
the mechanisms of action of the water soluble cinnamon
extract, CPF, in the context of diabetic complications.
Our sequencing data provides numerous gene targets
which will provide the basis for further interrogation.
Finally, this study was performed in transformed human
cell lines in normoglycemic conditions and further
experimentation will incorporate the use of normal cell
lines and hyperglycaemic conditions. Our analysis is
comprehensive with respect to diabetic wound healing
and further examination in cell culture systems will
involve the use of other relevant cell lines such as
fibroblasts and cells of the immune system. Given
limitations associated with cell culture studies further
it is preferable that further studies are conducted using
appropriate in vivo models and isolation of relevant cells
for analysis.
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